Sign In
Buy BMRN
$56.47
+1.81 (+3.31%)
At Close: Jun 04, 2026
BioMarin to Participate in the Virtual BofA Securities 2021 Napa Biopharma Conference
08:30am, Tuesday, 15'th Jun 2021
SAN RAFAEL, Calif., June 15, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in the BofA Securities 2021 Napa Biopharma Conference on
BioMarin: Too Soon To Buy
12:11pm, Wednesday, 02'nd Jun 2021
BioMarin product revenue has begun to decline. The outlook and guidance for 2021 is consistent with the modest decline reported in the first quarter. The next catalyst is likely November 2021 which is
BioMarin: Depressed Price Due To CRL, Major Catalysts Ahead
11:00pm, Monday, 31'st May 2021
BioMarin stock remains depressed since the August CRL. There are major catalysts ahead.
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
08:30am, Thursday, 27'th May 2021
SAN RAFAEL, Calif., May 27, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences.
BioMarin (BMRN) Hemophilia Gene Therapy Gets EMA's Speedy Review
12:02pm, Tuesday, 25'th May 2021
The EMA grants accelerated assessment to BioMarin's (BMRN) request for review of valoctocogene roxaparvovec for treating severe hemophilia A.
EMA Grants BioMarin's Request For Speedy Review of Hemophilia A Gene Therapy
12:11pm, Monday, 24'th May 2021
The European Medicines Agency (EMA) has granted its request for accelerated assessment review to BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) valoctocogene roxaparvovec, gene therapy to treat sev
SAN RAFAEL, Calif., May 24, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Medicines Agency (EMA) has granted its request for accelerated assessment
Five-Year Data Of BioMarin's Hemophilia Gene Therapy Shows Sustained Benefit
01:05pm, Wednesday, 19'th May 2021
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has announced an update to its previously reported results from Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment f
SAN RAFAEL, Calif., May 19, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results from an open-label Phase 1/2 study of valocto
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
08:30am, Tuesday, 18'th May 2021
SAN RAFAEL, Calif., May 18, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences.
BioMarin Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting
08:31am, Wednesday, 12'th May 2021
SAN RAFAEL, Calif., May 12, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced three oral and three poster presentations on valoctocogene roxaparvovec, an investigationa
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
08:30am, Monday, 03'rd May 2021
SAN RAFAEL, Calif., May 3, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences.
BioMarin (BMRN) Q1 Earnings Beat, FDA Delays Vosoritide Decision
10:31am, Friday, 30'th Apr 2021
BioMarin (BMRN) beats estimates for both earnings and revenues in the first quarter of 2021.
BioMarin Pharmaceutical Inc. (BMRN) CEO J.J. Bienaime on Q1 2021 Results - Earnings Call Transcript
11:24pm, Thursday, 29'th Apr 2021
BioMarin Pharmaceutical Inc. (BMRN) CEO J.J. Bienaime on Q1 2021 Results - Earnings Call Transcript
Biomarin Pharmaceutical: Q1 Earnings Insights
05:27pm, Thursday, 29'th Apr 2021
Shares of Biomarin Pharmaceutical (NASDAQ:BMRN) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 79.55% over the past year to $0
